Other names: sodium-glucose cotransporter-2 inhibitors
What are SGLT-2 inhibitors?
SGLT-2 inhibitor is an abbreviation for sodium-glucose cotransporter-2 inhibitors. SGLT-2 inhibitors are a class of medicine used to lower high blood glucose levels in people with type 2 diabetes. They may also be called gliflozins.
SGLT-2 inhibitors inhibit SGLT-2 proteins located in the renal tubules of the kidneys which are responsible for reabsorbing glucose back into the blood. As a result, more glucose is excreted in the urine. SGLT-2 inhibitors have been shown to be effective at lowering hemoglobin A1c levels, improving weight loss and lowering blood pressure. They carry a low risk of hypoglycemia (low blood sugar levels).
They are usually well tolerated. SGLT-2 inhibitors may be used in the treatment of type 2 diabetes and act independently of beta-cell function in the pancreas.
List of SGLT-2 inhibitors
|Drug Name||Avg. Rating||Reviews|
Generic name: empagliflozin
Generic name: canagliflozin
Generic name: dapagliflozin
Generic name: ertugliflozin
Generic name: bexagliflozin
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|
Medical conditions associated with SGLT-2 inhibitors:
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.